Form 4: Greenwich LifeSciences CEO and CFO, Snehal Patel, Reports Stock Option Grants

Snehal Patel, CEO and CFO of Greenwich LifeSciences, reported the acquisition of stock options, both directly and indirectly through his wife, on December 24, 2024.

Summary

• Snehal Patel, the CEO and CFO of Greenwich LifeSciences, has reported the acquisition of stock options.
• On December 24, 2024, Mr. Patel acquired 1,148,723 stock options directly and 25,008 stock options indirectly through his wife.
• The options have an exercise price of $12.16 and expire on December 24, 2034.
• The direct options vest over time, with a portion vesting immediately and the remainder vesting monthly over 36 months, with additional vesting based on employment duration.
• The indirect options also vest over time, with a portion vesting immediately and the remainder vesting monthly over 36 months.

Sentiment

Score: 7

Explanation: The document is a routine disclosure of stock option grants, which is generally positive as it aligns management with shareholders. There are no negative implications.

Positives

• The grant of stock options to the CEO and CFO aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with the long-term success of the company.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• Vesting schedules tied to employment duration are also common to incentivize long-term commitment.
• The specific terms of the grant, such as the exercise price and vesting schedule, are typical for a company of this size and stage.

Stakeholder Impact

• The stock option grants may be viewed positively by shareholders as they align management's interests with the company's long-term success.
• The vesting schedule encourages long-term commitment from the executive.

Key Dates

Keywords

stock options, insider trading, executive compensation, Greenwich LifeSciences, GLSI, Snehal Patel, vesting, equity